SCHEDULE 13D/A Filed 2026-09-09 Event 2026-09-07 SEC 0001104659-26-106301 →

HBM Healthcare Investments (Cayman) Ltd. → Chemomab Therapeutics Ltd. CMMB

Stake: — Shares: 80,971,680 Class: Ordinary shares, no par value per share

Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 23/100

Active Schedule 13D filer baseline
Short interest building (+31.7% vs prior settlement)

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

4 transactions

2 buys · 0 sales · 0 awards/exercises

Issuer Cluster

11 13D/G filings on this issuer

10 other filings besides this one

Filer Track Record

3 filings by this filer

2 other filings in the data moat

Short Interest · settle 2026-10-15

DTC 1.00

13,889 shares short · +31.7% vs prior

Form 4 Insider Transactions · last 365d

Date	Insider	Role	Type	Shares	Price	Value
2026-05-29	Mor George Adi	director, officer	Buy	4,878	$2.05	$10K
2026-05-29	Mor George Adi	director, officer	Buy	4,926	$2.08	$10K
2026-05-29	Mor George Adi	director, officer	J	31,712	—	—
2026-05-29	Mor George Adi	director, officer	J	18,750	—	—

Other 13D/G Filings on Chemomab Therapeutics Ltd.

Filed	Form	Filer	Stake	Shares
2026-07-16	SCHEDULE 13D	HBM Healthcare Investments (Cayman) Ltd.	12.50%	80,971,680	view →
2024-03-11	SC	OrbiMed Israel BioFund GP Limited Partnership	—	—	view →
2021-04-15	SC	Access Industries Holdings LLC	—	—	view →
2020-12-21	SC	Access Industries Holdings LLC	—	—	view →
2020-12-18	SC	Palisade Medical Equity I, LP	—	—	view →
2020-03-31	SC	Access Industries Holdings LLC	—	—	view →
2020-01-13	SC	Access Industries Holdings LLC	—	—	view →
2019-12-31	SC	Access Industries Holdings LLC	—	—	view →
2019-06-27	SC	Palisade Medical Equity I, LP	—	—	view →
2019-02-25	SC	Palisade Medical Equity I, LP	—	—	view →

Other Filings by HBM Healthcare Investments (Cayman) Ltd.

Filed	Form	Issuer	Stake	Shares
2026-10-13	SCHEDULE 13G	Vicore Pharma Holding AB	—	—	view →
2026-07-16	SCHEDULE 13D	Chemomab Therapeutics Ltd.	12.50%	80,971,680	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →